Literature DB >> 8806592

ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies.

Y Kita1, J Tseng, T Horan, J Wen, J Philo, D Chang, B Ratzkin, R Pacifici, D Brankow, S Hu, Y Luo, D Wen, T Arakawa, M Nicolson.   

Abstract

A panel of mAbs were generated against the purified soluble form of erbB2/Her2 receptor, corresponding to the extracellular region of the receptor, and examined for their ability to mimic the receptor ligand. Some of the mAbs strongly induced tyrosine phosphorylation of 180-185 kDa proteins, including not only Her2 but also Her3 and Her4 receptors, when they were expressed on the surface of breast cancer cells. These mAbs do not cross-react with Her3 or Her4 as demonstrated by competition study. Receptor phosphorylation was also observed with the cell lines transfected with Her2 or a chimeric receptor consisting of the extracellular domain of Her2 and the transmembrane and cytoplasmic domains of epidermal growth factor receptor. Selected mAbs were tested for their ability to change cell morphology, and one specific mAb, mAb74, induced cell morphology changes and apoptosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806592     DOI: 10.1006/bbrc.1996.1311

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Highly efficient selection of epitope specific antibody through competitive yeast display library sorting.

Authors:  Vinita Puri; Emily Streaker; Ponraj Prabakaran; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

2.  Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells.

Authors:  Dhong Hyo Kho; Pratima Nangia-Makker; Vitaly Balan; Victor Hogan; Larry Tait; Yi Wang; Avraham Raz
Journal:  Cancer Res       Date:  2012-12-17       Impact factor: 12.701

Review 3.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

Review 4.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

5.  Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.

Authors:  H Kunisue; J Kurebayashi; T Otsuki; C K Tang; M Kurosumi; S Yamamoto; K Tanaka; H Doihara; N Shimizu; H Sonoo
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells.

Authors:  G C Huang; S Hobbs; M Walton; R J Epstein
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.